Your browser doesn't support javascript.
A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.
Olivera-Ugarte, Santa-Mariela; Bolduc, Marilène; Laliberté-Gagné, Marie-Ève; Blanchette, Léa-Jeanne; Garneau, Caroline; Fillion, Maude; Savard, Pierre; Dubuc, Isabelle; Flamand, Louis; Farnòs, Omar; Xu, Xingge; Kamen, Amine; Gilbert, Mégan; Rabezanahary, Henintsoa; Scarrone, Martina; Couture, Christian; Baz, Mariana; Leclerc, Denis.
  • Olivera-Ugarte SM; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Bolduc M; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Laliberté-Gagné MÈ; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Blanchette LJ; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Garneau C; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Fillion M; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Savard P; Neurosciences, Laval University, 2705 boulevard Laurier, Québec City, QC G1V 4G2, Canada.
  • Dubuc I; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Flamand L; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Farnòs O; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montréal, QC H3A 0E9, Canada.
  • Xu X; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montréal, QC H3A 0E9, Canada.
  • Kamen A; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montréal, QC H3A 0E9, Canada.
  • Gilbert M; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Rabezanahary H; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Scarrone M; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Couture C; Quebec Heart and Lung Institute-Laval University, Department of Anatomic Pathology and Cytology, Québec City, QC G1V 4G5, Canada.
  • Baz M; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
  • Leclerc D; Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada. Electronic address: Denis.Leclerc@crchudequebec.ulaval.ca.
Nanomedicine ; 44: 102584, 2022 08.
Article in English | MEDLINE | ID: covidwho-1937030
ABSTRACT
A vaccine candidate to SARS-CoV-2 was constructed by coupling the viral receptor binding domain (RBD) to the surface of the papaya mosaic virus (PapMV) nanoparticle (nano) to generate the RBD-PapMV vaccine. Immunization of mice with the coupled RBD-PapMV vaccine enhanced the antibody titers and the T-cell mediated immune response directed to the RBD antigen as compared to immunization with the non-coupled vaccine formulation (RBD + PapMV nano). Anti-RBD antibodies, generated in vaccinated animals, neutralized SARS-CoV-2 infection in vitro against the ancestral, Delta and the Omicron variants. At last, immunization of mice susceptible to the infection by SARS-CoV-2 (K18-hACE2 transgenic mice) with the RBD-PapMV vaccine induced protection to the ancestral SARS-CoV-2 infectious challenge. The induction of the broad neutralization against SARS-CoV-2 variants induced by the RBD-PapMV vaccine demonstrate the potential of the PapMV vaccine platform in the development of efficient vaccines against viral respiratory infections.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nanomedicine Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: J.nano.2022.102584

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nanomedicine Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: J.nano.2022.102584